BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 29391287)

  • 1. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung.
    Kujtan L; Muthukumar V; Kennedy KF; Davis JR; Masood A; Subramanian J
    J Thorac Oncol; 2018 May; 13(5):707-714. PubMed ID: 29391287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis.
    Raman V; Jawitz OK; Yang CJ; Tong BC; D'Amico TA; Berry MF; Harpole DH
    Ann Thorac Surg; 2019 Aug; 108(2):377-383. PubMed ID: 31004586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
    Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
    J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy.
    Tanaka Y; Ogawa H; Uchino K; Ohbayashi C; Maniwa Y; Nishio W; Nakao A; Yoshimura M
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):839-46. PubMed ID: 22498090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
    Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
    Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.
    Sarkaria IS; Iyoda A; Roh MS; Sica G; Kuk D; Sima CS; Pietanza MC; Park BJ; Travis WD; Rusch VW
    Ann Thorac Surg; 2011 Oct; 92(4):1180-6; discussion 1186-7. PubMed ID: 21867986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience.
    Fournel L; Falcoz PE; Alifano M; Charpentier MC; Boudaya MS; Magdeleinat P; Damotte D; Régnard JF
    Eur J Cardiothorac Surg; 2013 Jan; 43(1):111-4. PubMed ID: 22529187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
    Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
    Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
    Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
    Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
    Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
    Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
    Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
    Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
    Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases.
    Veronesi G; Morandi U; Alloisio M; Terzi A; Cardillo G; Filosso P; Rea F; Facciolo F; Pelosi G; Gandini S; Calabrò F; Casali C; Marulli G; Spaggiari L
    Lung Cancer; 2006 Jul; 53(1):111-5. PubMed ID: 16697073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis.
    Yang Q; Xu Z; Chen X; Zheng L; Yu Y; Zhao X; Chen M; Luo B; Wang J; Sun J
    Thorac Cancer; 2019 Apr; 10(4):751-760. PubMed ID: 30734490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
    Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
    J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.